Background: Inactivated poliovirus vaccine (IPV) boosts mucosal immunity in persons previously vaccinated with oral poliovirus vaccine (OPV). We assessed whether fractional-dose IPV (fIPV, 1/5th of full dose) administered intradermally also boosts mucosal immunity. Methods: Children 10-12 years old were enrolled in Sri Lanka and randomized to receive one dose IPV, fIPV, or no IPV vaccine. One month later, they received OPV challenge. Blood was collected at enrolment and before challenge; stool was collected at 3, 7, and 14 days post-challenge. Sera were analysed for presence of poliovirus neutralizing antibodies; stool was analysed for poliovirus. Results: We analysed 304/309 (98%) enrolled subjects. There were 16/97 (16%), 9/99 (9%), and 72/95 (76%) subjects excreting poliovirus after challenge in the IPV, fIPV and "No IPV Vaccine" study arms, respectively (P < .001 for comparison of IPV [or fIPV] vs "No IPV Vaccine"; P = .1 for comparisons of fIPV vs IPV). Relative decrease in excretion prevalence was 80% and 88% to IPV and fIPV, respectively, compared with the "No IPV Vaccine" control arm. Conclusions: Single fIPV dose boosted mucosal immunity to a similar degree as single full dose of IPV. This finding provides further evidence in support of fIPV for poliovirus outbreak response at the time of IPV global supply shortage. Clinical trials registration: Australia New Zealand Clinical Trial Registry ACTRN12616000124437p.
Background: Inactivated poliovirus vaccine (IPV) boosts mucosal immunity in persons previously vaccinated with oral poliovirus vaccine (OPV). We assessed whether fractional-dose IPV (fIPV, 1/5th of full dose) administered intradermally also boosts mucosal immunity. Methods: Children 10-12 years old were enrolled in Sri Lanka and randomized to receive one dose IPV, fIPV, or no IPV vaccine. One month later, they received OPV challenge. Blood was collected at enrolment and before challenge; stool was collected at 3, 7, and 14 days post-challenge. Sera were analysed for presence of poliovirus neutralizing antibodies; stool was analysed for poliovirus. Results: We analysed 304/309 (98%) enrolled subjects. There were 16/97 (16%), 9/99 (9%), and 72/95 (76%) subjects excreting poliovirus after challenge in the IPV, fIPV and "No IPV Vaccine" study arms, respectively (P < .001 for comparison of IPV [or fIPV] vs "No IPV Vaccine"; P = .1 for comparisons of fIPV vs IPV). Relative decrease in excretion prevalence was 80% and 88% to IPV and fIPV, respectively, compared with the "No IPV Vaccine" control arm. Conclusions: Single fIPV dose boosted mucosal immunity to a similar degree as single full dose of IPV. This finding provides further evidence in support of fIPV for poliovirus outbreak response at the time of IPV global supply shortage. Clinical trials registration: Australia New Zealand Clinical Trial Registry ACTRN12616000124437p.
Authors: Nicholas C Grassly; Hamid Jafari; Sunil Bahl; Raman Sethi; Jagadish M Deshpande; Chris Wolff; Roland W Sutter; R Bruce Aylward Journal: J Infect Dis Date: 2012-03-23 Impact factor: 5.226
Authors: Edward Pk Parker; Natalie A Molodecky; Margarita Pons-Salort; Kathleen M O'Reilly; Nicholas C Grassly Journal: Expert Rev Vaccines Date: 2015-07-09 Impact factor: 5.217
Authors: Olen M Kew; Stephen L Cochi; Hamid S Jafari; Steven G F Wassilak; Eric E Mast; Ousmane M Diop; Rudolf H Tangermann; Gregory L Armstrong Journal: MMWR Morb Mortal Wkly Rep Date: 2014-11-14 Impact factor: 17.586
Authors: Jessica W Crothers; Elizabeth Ross Colgate; Kelly J Cowan; Dorothy M Dickson; MaryClaire Walsh; Marya Carmolli; Peter F Wright; Elizabeth B Norton; Beth D Kirkpatrick Journal: Vaccine Date: 2022-03-30 Impact factor: 4.169
Authors: Adedapo O Bashorun; Mariama Badjie Hydara; Ikechukwu Adigweme; Ama Umesi; Baba Danso; Njilan Johnson; Ngally Aboubacarr Sambou; Sidat Fofana; Francis J Kanu; Visalakshi Jeyaseelan; Harish Verma; William C Weldon; M Steven Oberste; Roland W Sutter; David Jeffries; Miriam Wathuo; Ondrej Mach; Ed Clarke Journal: Lancet Glob Health Date: 2021-12-21 Impact factor: 26.763
Authors: Ruth I Connor; Elizabeth B Brickley; Wendy F Wieland-Alter; Margaret E Ackerman; Joshua A Weiner; John F Modlin; Ananda S Bandyopadhyay; Peter F Wright Journal: Mucosal Immunol Date: 2021-07-08 Impact factor: 7.313